Format

Send to

Choose Destination
Cancer Res. 2016 Feb 1;76(3):513-6. doi: 10.1158/0008-5472.CAN-15-1737. Epub 2016 Jan 15.

A Breakthrough: Macrophage-Directed Cancer Immunotherapy.

Author information

1
BioMedical Consultants, Marine on St. Croix, Minnesota. mills002@umn.edu.
2
Immunology and Microbiology Department, University of Colorado School of Medicine, Aurora, Colorado.
3
Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Abstract

Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors. Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting molecules that actively stimulate tumor growth in much the same way they help wounds heal. However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth. The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells. Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone. That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality.

PMID:
26772756
PMCID:
PMC4738030
DOI:
10.1158/0008-5472.CAN-15-1737
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center